-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $100

Benzinga·11/10/2025 12:19:47
Listen to the news
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $85 to $100.